Samsung Biologics

Samsung Biologics is a publicly-traded biotechnology company that works in contract development and manufacturing (CDMO). The company is headquartered in Songdo, Incheon, South Korea as the biotech division of Samsung. It was founded in 2011.[1] From 2011 to 2018, Samsung Biologics built three manufacturing plants with a capacity of more than 360,000 liters, making it the world's largest contract-based manufacturer in the biopharmaceutical sector at a single site as of 2018.[2][3]

Samsung Biologics
Public
Traded asKRX: 207940
IndustryBiopharmaceuticals
Founded2011 (2011)
Headquarters
Songdo, Incheon
,
South Korea
Area served
Worldwide
Key people
Tae Han Kim, CEO
SubsidiariesSamsung Bioepis
Websitewww.samsungbiologics.com

In 2012, it established Samsung Bioepis, a biosimilar medicine producer, with Biogen.[4] The company has partnered with GlaxoSmithKline for biologics products,[5] UCB on the production of a clinical trial to treat supranuclear palsy[6] and Vir Biotechnology and CytoDyn on the manufacturing of monoclonal antibodies during the COVID-19 pandemic.[7][8] In November 2019, Samsung Biologics became the first contract manufacturing organization to obtain ISO 27001 certification.[9] The company also obtained an ISO 22301 certification in May 2020, the first in the Korean biopharma industry.[10]

References
  1. "Blazing Samsung Biologics trail into new territory". The Korea Herald.
  2. "Samsung BioLogics annual sales up 30% on contract research growth". Korea Biomedical Review.
  3. "Samsung Biologics to add new contract drug-making plant". The Korea Times.
  4. "Samsung BioLogics no longer a holding company of Samsung Bioepis". The Korea Herald.
  5. "GlaxoSmithKline hands Samsung Biologics $231M to scale up manufacturing". Fierce Pharma.
  6. "Samsung Biologics to produce clinical supply as UCB advances Ph I immunotherapy study". Outsourcing Pharma.
  7. "VirBio inks $362M Covid-19 contract manufacturing deal with Samsung Biologics". MedCity News.
  8. "Virtaps Samsung to produce coronavirus candidate". C&EN.
  9. "Samsung Biologics receives ISO certification". The Investor.
  10. "Samsung Biologics wins int'l standard for biz continuity (ISO22301) for its third plant". Korea IT Times.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.